ASX-listed clinical-stage oncology group, PharmAust, has taken the next significant step towards establishing whether its cancer fighting drug, Monepantel, can also inhibit COVID-19. The Perth-based company has struck an agreement with an internationally renowned biomedical research university in the Netherlands that will examine the suitability of Monepantel and Monepantel Sulfone for the all-important preclinical ex-vivo stage of testing that precedes the critical clinical trials.
24/09/2020 - 14:48
Netherlands COVID-19 researchers to test PharmAust drugs
By Matt Birney
24/09/2020 - 14:48
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 129th ResApp Health $3.8m 130th Emyria $3.8m 132nd Botanix Pharmaceuticals $3.8m 133rd Volt Power Group $3.6m 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX